If ACAD wants to buy NEU , the last thing they would do is announce a ph2 trial of 2591 in Retts or FXS. These trials cost about $20M each.
It’s hard to think of another reason they are so quiet about commencing work on them both.
Ann: DAYBUE (trofinetide) 2024 net sales US$348 million, page-29
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$17.29 |
Change
0.660(3.97%) |
Mkt cap ! $2.178B | |||
| Open | High | Low | Value | Volume |
| $16.80 | $17.34 | $16.63 | $9.078M | 529.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1334 | $17.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.33 | 2245 | 3 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |